Monoclonal antibody to understand the role of BORIS protein in prostate cancers.
| Inventor | Institute |
|---|---|
| Elena Klenova | University of Essex |
| Cat. #: | 151848 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer;Genetics |
| Application: | ChIP ; ELISA ; IF ; IP ; WB |
| Target: | BORIS |
| Reactivity: | Human |
| Clone: | 4A7 |
| Host: | Mouse |
| Class: | Monoclonal |
| Alternate name: | Brother of the regulator of imprinted sites, Cancer/testis antigen 27, CCCTC binding factor (zinc finger protein) like, CCCTC-binding factor, CT27, CTCF paralog, CTCF T, CTCF-like protein, Ctcfl, CTCFL_HUMAN, dJ579F2.2, HMG 1L1, HMGB1L1, MGC163358, MGC16915, MGC16916 |
|---|---|
| Product description: | Monoclonal antibody to understand the role of BORIS protein in prostate cancers. |
| Conjugation: | Unconjugated |
| Isotype: | IgM kappa |
| Molecular weight: | 83 kDa |
| Immunogen: | The N-terminal domain (aa 2-257) of human BORIS (CTCFL) protein, expressed in E.coli |
| Immunogen Uniprot ID: | Q8NI51 |
| Target background: | BORIS protein is a transcriptional repressor encoded by CTCFL gene, and is normally present at high levels in testis. BORIS protein has been identified as Cancer-Testis Antigen (CTA) with testis-specific paralogue of the CCCTC-binding factor. Recent studies have demonstrated that BORIS is directly responsible for the transcriptional activation of TSP50 (testes-specific protease 50). BORIS protein is detected in all prostate cell lines and prostate tumours, but it is absent in benign prostatic hyperplasia tissues. Increased BORIS protein levels correlate with higher Gleason scores, T-stage and androgen receptor (AR) protein levels in prostate tumours. This reagent is for research and as a diagnostic tool. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | Store at -20° C frozen. Avoid repeated freeze / thaw cycles |
| Shipping conditions: | Dry ice |
| References: |
Cheema et al. 2014. Prostate. 74(2):164-76. PMID: 24123052. Expression of the cancer-testis antigen BORIS correlates with prostate cancer. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151030 | Anti-Progesterone [11P14] |
Key Info
Anti-Progesterone [11P14]
|
View Tool | |||||||||||||||||||
| 151021 | Anti-CyclinB1 [V152] |
Key Info
Anti-CyclinB1 [V152]
|
View Tool | |||||||||||||||||||
| 151022 | Anti-IL12 [1-1A4] |
Key Info
Anti-IL12 [1-1A4]
|
View Tool | |||||||||||||||||||
| 151025 | Anti-Vascular endothelium [10] |
Key Info
Anti-Vascular endothelium [10]
|
View Tool | |||||||||||||||||||
| 151026 | Anti-FCGR1 [10.1] mAb |
Key Info
Anti-FCGR1 [10.1] mAb
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.